NCT02860000 2026-02-27Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerMayo ClinicPhase 2 Completed96 enrolled 34 charts
NCT01091428 2018-06-04Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast CancerTakedaPhase 2 Completed191 enrolled 39 charts